FDA approves IV formulation of Merck's Noxafil

FDA approved an NDA for an IV formulation of antifungal agent Noxafil posaconazole from Merck & Co. Inc. (NYSE:MRK) for prophylaxis of invasive Aspergillus and Candida infections in severely immunocompromised patients. The pharma plans to launch the product in the U.S. in mid-April. An MAA for the IV formulation is under EMA review. ...